• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To register, simply click the Register button at the top right.

SNP rs28359483, NAT1 & MCS

LaurieL

Senior Member
Messages
447
Location
Midwest
While looking for some SNP's I found this concerning Multiple Chemical Sensitivity.

Int J Epidemiol. 2004 Oct;33(5):971-8. Epub 2004 Jul 15.
Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR.

McKeown-Eyssen G, Baines C, Cole DE, Riley N, Tyndale RF, Marshall L, Jazmaji V.

Source
Departments of Public Health Sciences, University of Toronto, ON, Canada. gail.eyssen@utoronto.ca

Abstract
BACKGROUND:
Impaired metabolism of toxic chemicals is a postulated mechanism underlying multiple chemical sensitivity (MCS). Because genetic variation alters the rate of chemical metabolism, this study was designed to determine if MCS cases differed from controls for genetic polymorphisms in drug-metabolizing enzymes.

METHODS:
Female Caucasian participants (203 cases and 162 controls) were drawn from a larger case-control study based on a reproducible and validated case definition. Common polymorphisms for CYP2D6, NAT1, NAT2, PON1, and PON2 were genotyped.

RESULTS:
Comparing cases and controls, significant differences were found in genotype distributions for CYP2D6 (P = 0.02) and NAT2 (P = 0.03). Compared with the referent homozygous inactive (CYP2D6) or slow (NAT2) metabolizers, the odds for being CYP2D6 homozygous active (OR = 3.36, P = 0.01) and NAT2 rapid (OR = 4.14, P = 0.01) were significantly higher in cases than controls. The odds for being heterozygous for PON1-55 (OR = 2.05, P = 0.04) and PON1-192 (OR = 1.57, P = 0.04) were also significantly higher in cases.

CONCLUSIONS:
A genetic predisposition for MCS may involve altered biotransformation of environmental chemicals. The CYP2D6 enzyme activates and inactivates toxins; the NAT2 enzyme bioactivates arylamines to protein-binding metabolites. A gene-gene interaction between CYP2D6 and NAT2 suggested that rapid metabolism for both enzymes may confer substantially elevated risk (OR = 18.7, P = 0.002). Our finding parallels others' observation of a link between PON1 heterozygosity and neurological symptoms in Gulf War syndrome. This first demonstration of genetic variation in drug-metabolizing enzymes in association with MCS requires replication. However, it suggests new research directions on genetically variable toxin pathways that might be important in MCS.

PMID: 15256524 [PubMed - indexed for MEDLINE]

Interestingly enough, I have multiple SNP's for CYP2D6 that are abnormal.

http://snp-nexus.org/temp/snpnexus_19971/results.html
 

LaurieL

Senior Member
Messages
447
Location
Midwest
CYP2D6

I have several SNP's in the CYP2D6 enzyme. Interestingly, I have had three anaphylactic reactions in my lifetime. And the drugs I had those reactions to are considered substrates in the CYP2D6.

Laurie
 

hixxy

Senior Member
Messages
1,229
Location
Australia
Interested in how you interpreted your 23andme results for these genes? How is the genotype field interpreted? I have pretty extreme MCS and would definitely like to know more about these genes...